Twist’s antibody agenda grows with Abveris deal

Acquiring Abveris deepens Twist’s dive into antibody discovery, where the processes the company developed to manufacture DNA gives it the throughput required to go after difficult targets.

Twist Bioscience Corp. (NASDAQ:TWST) has been growing its footprint in antibody discovery since hiring CSO Aaron Sato, a “bona fide drug developer,” about three years ago, CEO Emily Leproust told BioCentury. She said that as the company developed a track record for delivering antibody-encoding DNA constructs, “we felt we had an opportunity to go up the value chain” by building out a biopharma unit. ...